AETHLON MEDICAL, INC. (NASDAQ:AEMD) Files An 8-K Regulation FD Disclosure

AETHLON MEDICAL, INC. (NASDAQ:AEMD) Files An 8-K Regulation FD Disclosure

Story continues below

ITEM 7.01

REGULATION FD DISCLOSURE.

On March 14, 2017, Mr. James Joyce, Chief Executive Officer of
Aethlon Medical, Inc. (the Company), presented at the
29th Annual Roth Conference. A link to the
presentation may be accessed on the Companys website under the
investor relations section of the website. The website address is
www.aethlonmedical.com. No portion of the website shall be deemed
to be incorporated into this Current Report on Form 8-K.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) EXHIBITS
EXHIBIT NO. DESCRIPTION
99.1 Presentation materials 29th Annual Roth Conference
March 14, 2017


About AETHLON MEDICAL, INC. (NASDAQ:AEMD)

Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.

AETHLON MEDICAL, INC. (NASDAQ:AEMD) Recent Trading Information

AETHLON MEDICAL, INC. (NASDAQ:AEMD) closed its last trading session up +0.29 at 4.69 with shares trading hands.

An ad to help with our costs